Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Influenza vaccine - BiondVax

Drug Profile

Influenza vaccine - BiondVax

Alternative Names: BVX-M001; M 001; Multimeric Multi-Epitope Polypeptide Influenza Vaccine; Multimeric-001; Multimeric-001 Universal Flu Vaccine - BiondVax; Universal Flu Vaccine - BiondVax

Latest Information Update: 29 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Weizmann Institute of Science
  • Developer BiondVax Pharmaceuticals; National Institutes of Health
  • Class Influenza virus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Influenza virus infections

Most Recent Events

  • 18 Nov 2019 BiondVax completes enrolment in a phase III trial for Influenza virus infections (Prevention) in Bulgaria, Croatia, Georgia, Hungary, Latvia, Poland and Ukraine (IM) (EudraCT2018-000468-27) (NCT03450915)
  • 18 Jun 2019 BiondVax Pharmaceuticals Ltd. receives patent covering formulation and production processes of M 001 in the US and Japan
  • 15 Apr 2019 BiondVax Pharmaceuticals has patent pending for M 001 in Europe, China, Japan and USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top